Rosuvastatin
- PDF / 170,979 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 170 Views
1
S
Bilateral neurotrophic keratopathy: case report A 65-year-old woman developed neurotrophic keratopathy during treatment with rosuvastatin for hyperlipidaemia. The woman presented in May 2018 with painless diminution of vision in both eyes of gradual onset and progressive course for 1 month. Two weeks after the onset of diminution of vision, she was diagnosed with bilateral corneal ulcers, and she was prescribed unspecified tear substitutes and topical antibiotic. However, no improvement was observed. In March 2018, she had started receiving rosuvastatin 10mg [route not stated] for dyslipidaemia. Additionally, she had been treated with unspecified β-blocker for hypertension. In June 2018, her corrected distance visual acuity score in both eyes was 20/600, while external ocular examination showed normal results with full ocular motility. An anterior segment examination of both eyes showed large clean middle corneal epithelial defects, which were extended to the limbus in association with ciliary injection and smooth rolled edges. These findings were consistent with stage II neurotrophic keratopathy. Her corneal sensation were diminished bilaterally, and an anterior chamber examination was free in both the eyes. A brain MRI and neurological examination were unremarkable. Due to temporal association with rosuvastatin initiation, drug-related neurotrophic keratopathy was suspected. Hence, the woman’s therapy with rosuvastatin was stopped. Subsequently, bilateral patching was done, and after discontinuation of rosuvastatin, the corneal epithelial defect significantly improved. The neurotrophic keratopathy resolved rapidly. Patching was replaced with therapeutic contact lenses, and she was treated with an unspecified topical antibiotic for prophylaxis. After 1 week, improvement in corrected distance visual acuity was noted. A corneal epithelial defect completely healed in the left eye, while improved in the right eye. Also, partial recovery of corneal sensation was noted. She was advised about not to re-start rosuvastatin, and after 1 year (June 2019), she had only mild bilateral residual anterior stromal opacification with no recurrence of ulceration. Author comment: "We report a case of bilateral stage 2 neurotrophic keratopathy that was temporally associated with initiation of rosuvastatin therapy and that rapidly resolved following drug discontinuation." "According to the World Health Organization criteria on drug-related adverse events, a probable association between a drug and an adverse event is made". Elnahry AG, et al. Reversible neurotrophic keratopathy associated with rosuvastatin therapy: A case report. Journal of Population Therapeutics and Clinical Pharmacology 26: e38-e42, No. 2, 13 Aug 2019. Available from: URL: 803432537 https://www.jptcp.com/index.php/jptcp - Egypt
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
